Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?

Journal of Internal Medicine

Volumn 264, Issue 5, 2008, Pages 481-492

  Van Staa, T P ^a,b   Rietbrock, S ^a   Setakis, E ^a   Leufkens, H G M ^b  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cox 2 inhibitors; Myocardial infarction; NSAIDs; Utilization patterns

Indexed keywords

ACETYLSALICYLIC ACID; DICLOFENAC; IBUPROFEN; INDOMETACIN; MEFENAMIC ACID; MELOXICAM; NAPROXEN; PIROXICAM;

ADULT; AGED; ARTICLE; ATTRIBUTABLE RISK; CONTROLLED STUDY; CORONARY RISK; DISEASE SEVERITY; DRUG EXPOSURE; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; UNITED KINGDOM;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; IBUPROFEN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NAPROXEN; SEX FACTORS; TIME FACTORS;

EID: 53549094147     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2008.01991.x     Document Type: Article

References (37)

1. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005 352 : 1092 102.
2. Solomon SD, McMurray JJV, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005 352 : 1071 80.
3. Nussmeier NA, Whelton AA, Brown MT et al. Complications of the Cox-2 inhibitors, Parecoxib and Valdecoxib after cardiac surgery. N Engl J Med 2005 352 : 1081 91.
4. Psaty BM, Furberg CD. COX-2 inhibitors - lessons in drug safety. N Engl J Med 2005 352 : 1133 5.
5. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998 104 : 413 21.
6. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006 296 : 1633 44.
7. MacDonald TM, Morant SV, Goldstein JL, Burke TA, Pettitt D. Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut 2003 52 : 1265 70.
8. Sift R, van Staa TP, Abenhaim L, Ebner D. A study of the longitudinal utilization and switching patterns of non-steroidal anti-inflammatory drugs using a pharmacy based approach. Pharmacoepidemiol Drug Saf 1997 6 : 263 8.
9. Leufkens HG, Ameling CB, Hekster YA, Bakker A. Utilization patterns of non-steroidal anti-inflammatory drugs in an open Dutch population. Pharm Weekbl Sci 1990 12 : 97 103.
10. Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997 350 : 1097 9.
11. Anderson KM, Odell PM, Wilson WF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1990 121 : 293 8.
12. Ramlau-Hansen H. Smoothing counting process intensities by means of kernel functional. Ann Statist 1983 11 : 453 66.
13. Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 2007 370 : 2138 51.
14. Fisher LM, Schlienger RG, Matter C, Jick H, Meier CR. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 2004 93 : 198 200.
15. Salpeter SR, Gregor P, Ormiston TM et al. Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am J Med 2006 119 : 552 9.
16. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006 332 : 1302 8.
17. Farkouh ME, Kirshner H, Harrington RA et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004 364 : 675 84.
18. Lisse JR, Perlman M, Johansson G et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med 2003 139 : 539 46.
19. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000 343 : 1520 8.
20. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000 284 : 1247 55.
21. Singh G, Fort JG, Goldstein JL et al. SUCCESS-I Investigators. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006 119 : 255 66.
22. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. MEDAL Steering Committee. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007 369 : 465 73.
23. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Design characteristics of included trials. BMJ 2006 332 : 1302 8. http://www.bmj.com/ cgi/content/full/332/7553/1302/DC1 [downloaded 17 May, 2007].
24. Thompson SG, Pocock SJ. Can meta-analyses be trusted? Lancet 1991 338 : 1127 30.
25. Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the touble with averages. Milbank Q 2004 82 : 661 87.
26. Gislason GH, Jacobsen S, Rasmussen JN et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006 113 : 2906 13.
27. Graham DJ, Campen D, Hui R et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005 365 : 475 81.
28. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001 345 : 1809 17.
29. de Vries F, Pouwels S, Bracke M et al. Use of beta-2 agonists and risk of acute myocardial infarction in patients with hypertension. Br J Clin Pharmacol 2008 65 : 580 6.
30. García Rodríguez LA, Varas-Lorenzo C, Maguire A et al. Non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004 109 : 3000 6.
31. García Rodríguez LA, Varas-Lorenzo C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000 11 : 383 7.
32. Schlienger R, Jick H, Meier C. Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br J Clin Pharmacol 2002 54 : 327 32.
33. Fisher LM, Schlienger RG, Matter CM, Jick H, Meier CR. Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Arch Intern Med 2004 164 : 2472 6.
34. Fisher LM, Schlienger RG, Matter CM, Jick H, Meier CR. Current use of nonsteroidal anti-inflammatory drug therapy and the risk of acute myocardial infarction. Pharmacotherapy 2005 25 : 503 10.
35. Jick H, Kaye JA, Russmann S, Jick SS. Nonsteroidal antiinflammatory drugs and acute myocardial infarction in patients with no major risk factors. Pharmacotherapy 2006 26 : 1379 87.
36. Jick SS, Kaye JA, Jick H. Diclofenac and acute myocardial infarction in patients with no major risk factors. Br J Clin Pharmacol 2007 64 : 662 7.
37. Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006 113 : 1950 7.